Disc Medicine claims PhII win for repurposed ex-Roche drug in rare blood disorder
When Disc Medicine closed a $62.5 million raise led by Bain Capital earlier this year, the biotech’s CEO John Quisel pointed to the stream of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
